Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SYS6043 versus investigator's choice chemotherapy as first-line treatment for unresectable locally recurrent or metastatic triple-negative breast cancer
CTR20263827Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SYS6043 in triple-negative breast cancer (TNBC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Oct 2026; status: active.
02
Drugs
SYS6043
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20263827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263827.